Guggenheim analyst Seamus Fernandez started Eli Lilly with a Buy rating and $132 price target, calling out the company’s “Impressive execution as the industry’s leading fast-follower.” He sees limited downside from current levels with the potential for revaluation around the Phase 3 study readout for tanezumab.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.